Arcalyst
Total Payments
$3.1M
Transactions
39,606
Doctors
14,947
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.6M | 22,053 | 11,006 |
| 2023 | $701,005 | 12,563 | 7,347 |
| 2022 | $809,477 | 4,990 | 3,039 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $894,871 | 38,472 | 29.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $867,284 | 329 | 28.2% |
| Unspecified | $458,583 | 64 | 14.9% |
| Space rental or facility fees (teaching hospital only) | $262,070 | 45 | 8.5% |
| Travel and Lodging | $153,018 | 567 | 5.0% |
| Consulting Fee | $134,555 | 65 | 4.4% |
| Royalty or License | $126,760 | 10 | 4.1% |
| Honoraria | $93,585 | 30 | 3.0% |
| Grant | $45,900 | 12 | 1.5% |
| Education | $24,735 | 11 | 0.8% |
| Charitable Contribution | $10,000 | 1 | 0.3% |
Payments by Type
General
$2.6M
39,542 transactions
Research
$458,583
64 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study with Open-Label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects with Recurrent Pericarditis (RHAPSODY) | Kiniksa Pharmaceuticals, Ltd. | $295,924 | 0 |
| PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY WITH OPEN-LABEL EXTENSION, TO ASSESS THE EFFICACY AND SAFETY OF RILONACEPT TREATMENT IN SUBJECTS WITH RECURRENT PERICARDITIS (RHAPSODY) | Kiniksa Pharmaceuticals, Ltd. | $151,016 | 0 |
| A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | Kiniksa Pharmaceuticals International, plc | $11,643 | 0 |
Top Doctors Receiving Payments for Arcalyst
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $928,206 | 146 |
| , MBBCHBAO | Cardiovascular Disease | Salt Lake City, UT | $141,269 | 159 |
| , MD | Cardiovascular Disease | Pittsburgh, PA | $140,066 | 142 |
| , M.D | Cardiovascular Disease | Opelousas, LA | $72,329 | 86 |
| , M.D | Interventional Cardiology | Houston, TX | $66,788 | 83 |
| , M.D | Cardiovascular Disease | Phoenix, AZ | $53,217 | 53 |
| , M.D | Cardiovascular Disease | La Jolla, CA | $46,341 | 64 |
| , M.D | Cardiovascular Disease | Houston, TX | $42,587 | 45 |
| , MD | Rheumatology | New York, NY | $39,887 | 41 |
| , MD | Cardiovascular Disease | New York, NY | $39,086 | 48 |
| , M.D | Cardiovascular Disease | Irvine, CA | $36,064 | 45 |
| , M.D., M.S | Internal Medicine | Los Angeles, CA | $33,967 | 60 |
| , MD | Cardiovascular Disease | Virginia Beach, VA | $33,313 | 34 |
| , M.D | Specialist | Beverly Hills, CA | $30,808 | 32 |
| , MD | Cardiovascular Disease | La Mesa, CA | $27,830 | 49 |
| , M.D | Cardiovascular Disease | Charlottesville, VA | $26,588 | 29 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Omaha, NE | $25,307 | 32 |
| , MD | Cardiovascular Disease | Nashville, TN | $25,179 | 24 |
| , M.D | Internal Medicine | Manhasset, NY | $23,291 | 43 |
| , MD | Cardiovascular Disease | Overland Park, KS | $23,264 | 10 |
| , M.D | Cardiovascular Disease | York, PA | $21,178 | 22 |
| , DO | Cardiovascular Disease | Saint Johns, MI | $20,228 | 25 |
| , MD | Cardiovascular Disease | Cincinnati, OH | $17,629 | 19 |
| Michael Portman | Pediatric Cardiology | Seattle, WA | $17,085 | 9 |
| , MD | Cardiovascular Disease | Cleveland, OH | $16,577 | 23 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 14,947
- Transactions 39,606
About Arcalyst
Arcalyst is a drug associated with $3.1M in payments to 14,947 healthcare providers, recorded across 39,606 transactions in the CMS Open Payments database. The primary manufacturer is Kiniksa Pharmaceuticals, Ltd..
Payment data is available from 2022 to 2024. In 2024, $1.6M was paid across 22,053 transactions to 11,006 doctors.
The most common payment nature for Arcalyst is "Food and Beverage" ($894,871, 29.1% of total).
Arcalyst is associated with 3 research studies, including "Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study with Open-Label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects with Recurrent Pericarditis (RHAPSODY)" ($295,924).